abstract |
The present invention provides a complement factor D inhibitor compound comprising formula I or a pharmaceutically acceptable salt thereof, a method for using the same, a method for preparing the same, or a composition, wherein R 12 or R 13 on the A group is aryl, heteroaryl or heterocyclyl (R 32 ). The inhibitors described herein target factor D and inhibit or modulate the complement cascade at early and essential points in the alternative complement pathway, and reduce the ability of factor D to regulate the classical and lectin complement pathways. The inhibitors of Factor D described herein are able to reduce the overactivation of complement that is associated with certain autoimmune, inflammatory and neurodegenerative diseases as well as ischemia-reperfusion injury and cancer. |